))
PT Inquest is an online journal club. Hosted by Erik Meira and JW Matheson, the show looks at an article every week and discusses how they apply to current physical therapy practice.
What Novel Combination Strategies Are Being Studied for Anti-Drug Conjugates in Urothelial Cancer?
Manage episode 352046796 series 3128163
Creato da ReachMD, autore scoperto da Player FM e dalla nostra community - Il copyright è detenuto dall'editore, non da Player FM, e l'audio viene riprodotto direttamente dal suo server. Clicca sul pulsante Iscriviti per rimanere aggiornato su Player FM, o incolla l'URL del feed in un altra app per i podcast.
CME credits: 1.50
Valid until: 17-11-2023
Claim your CME credit at https://reachmd.com/programs/cme/what-novel-combination-strategies-are-being-studied-for-anti-drug-conjugates-in-urothelial-cancer/14441/
The approval of 2 antibody-drug conjugates (ADCs), enfortumab vedotin-ejfv (EV) and sacituzumab govitecan-hziy (SG), provide new treatment options to extend the lives of patients with urothelial cancer. Due to the recent nature of these approvals, clinicians may not be familiar with the mechanism of action of these ADCs and the pathways they target. Clinicians may not be aware of how ADCs fit into the current treatment landscape and may not be familiar with the evidence supporting their use. This educational program aims to increase clinician knowledge of the mechanism of action and evidence supporting the use of ADCs in cisplatin-eligible or -ineligible patients with advanced or metastatic urothelial carcinoma while teaching strategies for managing unique treatment-related adverse events associated with these agents.
Valid until: 17-11-2023
Claim your CME credit at https://reachmd.com/programs/cme/what-novel-combination-strategies-are-being-studied-for-anti-drug-conjugates-in-urothelial-cancer/14441/
The approval of 2 antibody-drug conjugates (ADCs), enfortumab vedotin-ejfv (EV) and sacituzumab govitecan-hziy (SG), provide new treatment options to extend the lives of patients with urothelial cancer. Due to the recent nature of these approvals, clinicians may not be familiar with the mechanism of action of these ADCs and the pathways they target. Clinicians may not be aware of how ADCs fit into the current treatment landscape and may not be familiar with the evidence supporting their use. This educational program aims to increase clinician knowledge of the mechanism of action and evidence supporting the use of ADCs in cisplatin-eligible or -ineligible patients with advanced or metastatic urothelial carcinoma while teaching strategies for managing unique treatment-related adverse events associated with these agents.
1519 episodi
